Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | PLK1 | P53350 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.45 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CCR6 | P51684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4009836 | 0.85 | CA1 (0.56) | MAPTPLK1RAB9ACA12CA1 | |
| SCHEMBL4003913 | 0.85 | CA1 (0.56) | MAPTPLK1RAB9ACA12CA1 | |
| SCHEMBL4281255 | 0.81 | CA1 (0.54) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL6815303 | 0.80 | LMNA (0.58) | RAB9ACA12CA1CA2CA7 | |
| SCHEMBL2341097 | 0.79 | MAPT (0.82) | MAPTPLK1RAB9ACA1CA2 | |
| SCHEMBL3996757 | 0.79 | CYP4A11 (0.55) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL4280831 | 0.78 | CA12 (0.50) | MAPTPLK1RAB9ACA12CA1 | |
| SCHEMBL3998464 | 0.78 | SLC5A1 (0.48) | PLK1SMN1; SMN2KMT2ASLC5A1SLC5A2 | |
| SCHEMBL4287936 | 0.77 | CYP4A11 (0.67) | MAPTCA12CA1CA2CA7 | |
| Methylamine SCHEMBL2429643 | 0.76 | MAPT (0.77) | MAPTPLK1RAB9ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541341-B2 | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-7465712-B2 | Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-12-16 | — | — | US | disclosed |
| US-7045665-B2 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-05-16 | — | — | US | disclosed |
| EP-1367060-B1 | GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-1270584-B1 | GLUCOPYRANOSYLOXY BENZYLBENZENE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THE PREPARATION OF THE DERIVATIVES | KISSEI PHARMACEUTICAL (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-20050080022-A1 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives | KISSEI PHARMACEUTICAL CO., LTD. | 2005-04-14 | — | — | US | disclosed |
| US-20050075294-A1 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives | KISSEI PHARMACEUTICAL CO., LTD. | 2005-04-07 | — | — | US | disclosed |
| US-20040138148-A1 | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| US-20040053855-A1 | Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives | KISSEI PHARMACEUTICAL CO & LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1367060-A1 | GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-12-03 | — | — | EP | disclosed |
| EP-1270584-A1 | GLUCOPYRANOSYLOXY BENZYLBENZENE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THE PREPARATION OF THE DERIVATIVES | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053855-A1 | Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives | SLC5A2, SLC5A1, SLC2A2 | MAPT 2633/4885PLK1 4866/4885RAB9A 2544/4885 |
| US-20050075294-A1 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives | SLC5A2, SLC5A1, SLC2A2 | MAPT 2674/4885PLK1 4845/4885RAB9A 2543/4885 |
| US-20040138148-A1 | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof | SLC5A2, SLC5A1, SLC2A1 | MAPT 2509/4885PLK1 4882/4885RAB9A 1749/4885 |
| US-20050080022-A1 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives | SLC5A2, SLC5A1, SLC2A2 | MAPT 2674/4885PLK1 4845/4885RAB9A 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.